Cystic Fibrosis Therapeutics Market, 2022

Dublin, July 25, 2017 -- The "Global Cystic Fibrosis Therapeutics Market Outlook 2022" report has been added to Research and Markets' offering.

The market for cystic fibrosis therapeutics was valued at US$ 1.94 Billion in 2016.

The report provides an in-depth analysis of all the major segments, taking into account the major developments taking place at global level in the respective segments that will further boost the growth of cystic fibrosis therapeutics market.

The Global Cystic Fibrosis Therapeutics industry has reported a tremendous growth in the recent years, and is presenting ample opportunities to the industry players. With improving life expectancy and rising awareness, the global cystic fibrosis therapeutics market is poised to scale newer acmes. Also, there lies enormous opportunity for industry participants to tap the fast growing market, which would garner huge revenue on the back of rising strategic consolidations and commercialization of the new drugs targeting the CFTR gene or protein.

The report showcases the segmentation of cystic fibrosis therapeutics market on the basis of the pharmacological class, mutation class, drug molecule type, and geographical penetration. It also provides an insight on the current market scenario, as well as forecasts of the aforementioned segments till 2022. The report provides an in-depth analysis of all the major segments, taking into account the major developments taking place at global level in the respective segments that will further boost the growth of cystic fibrosis therapeutics market.

Based on pharmacological class, the report broadly categorizes cystic fibrosis therapeutics market into Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Mucolytic agents, Pancreatic Enzymes products, Antibiotics, and Other therapies. CFTR modulators emerged as the major revenue earners of the industry, holding the largest share. This large share of the market is attributed to recent market approvals of Kalydeco (ivacaftor) and Orkambi (lumacaftor and ivacaftor) for the treatment of patients with CF and robust pipeline.

Based on CF mutation class, the cystic fibrosis therapeutics market is further categorized into commercialized and non-commercialized mutation class specific therapies. CFTR mutation Class II accounted for largest share in the total cystic fibrosis therapeutics market in 2016.

Based on drug molecule type, the cystic fibrosis therapeutics market is further categorized into small molecule and biologic. The small molecule segment accounted for largest share in the total cystic fibrosis therapeutics market in 2016.

Additionally, the report covers the geographic analysis of the global cystic fibrosis therapeutics market by segmenting into three major geographic regions - North America, Europe, and Asia Pacific. North America is the largest market for cystic fibrosis. This high share is attributed to increasing awareness in the market, coupled with growing research initiatives. However, the European market is poised to witness the highest growth owing to increasing focus of players in this region.

Besides, the report covers the profiles of key players like Genentech, Inc. (A Member of the Roche Group), Novartis, Vertex Pharmaceuticals Incorporated, Abbott Laboratories, Gilead Sciences, Inc., Allergan plc, etc. with the key financials, providing a comprehensive outlook of global cystic fibrosis therapeutics industry. In addition, the report elucidates key developments of players related to cystic fibrosis industry. Overall, the report provides all the pre-requisite information for clients looking to venture in this industry, and facilitate them to formulate schemes while going for an investment/partnership in the industry.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Cystic Fibrosis: An Overview

4. Market Dynamics
4.1 Drivers
4.1.1 Robust Pipeline
4.1.2 Rising Prevalence of Cystic Fibrosis
4.1.3 Rising Life expectancy of Cystic Fibrosis Patient's
4.1.4 Improvement in Diagnostic Technologies
4.1.5 Increasing Awareness
4.1.6 Unmet Medical Needs
4.2 Restraints
4.2.1 Cystic Fibrosis Related Complications
4.2.2 Increased Risk of Bacterial Infections in Cystic Fibrosis Patients
4.2.3 High Cost
4.3 Opportunities
4.3.1 Patent Expiry of Biggest-Selling Drugs
4.3.2 Gene Therapy Breakthrough for Cystic Fibrosis

5. Global Cystic Fibrosis Therapeutics Market Outlook 2022

6. Major Marketed Products
6.1 Orkambi (lumacaftor/ivacaftor)
6.2 Kalydeco (Ivacaftor)
6.3 Cayston (Inhaled Aztreonam)
6.4 Pulmozyme (Dornase Alfa)
6.5 TOBI
6.6 Creon
6.7 Zenpep
6.8 Ventolin
6.9 Bronchitol (Inhaled Mannitol)
6.10 ADEKplusTM
6.11 Ibuprofen

7. Market Segmentation by Pharmacological Class
7.1 CFTR modulators
7.2 Mucolytic Agents
7.3 Pancreatic Enzyme Replacement Products
7.4 Antibiotics
7.5 Other Therapies

8. Market Segmentation by Drug Molecule
8.1 Small Molecule
8.2 Biologic Drugs

9. Market Segmentation by Cystic Fibrosis Mutation Type
9.1 Commercialized
9.1.1 Class I
9.1.2 Class II
9.1.3 Class III
9.2 Non-Commercialized
9.2.1 Class IV
9.2.2 Class V
9.2.3 Class VI

10. Market Segmentation by Geography
10.1 North America
10.2 Europe
10.3 Asia Pacific

11. Industry Trends & Developments
11.1 Genetic Testing
11.2 Technological Advances
11.3 CFTR Modulators - Gaining Momentum
11.4 Upsurge in the Number of Strategic Alliances
11.5 Combination Therapy
11.6 Co-pay and Assistance Programs by Vendors
11.7 Increased R&D Activities: Pillars for Market Growth

12. Cystic Fibrosis Pipeline Analysis
12.1 Pipeline Analysis by Phase of Development
12.2 Pipeline Analysis by Key Players
12.3 Pipeline Analysis by Geography
12.4 Pipeline Analysis by Routes of Administration

13. Porter's Five Forces Analysis

14. Competitive Landscape
14.1 Share of Major Players

15. Company Profiles
15.1 Genentech, Inc. (A Member of the Roche Group)
15.2 Novartis
15.3 Vertex Pharmaceuticals Incorporated
15.4 Abbott Laboratories
15.5 Gilead Sciences, Inc.
15.6 Johnson & Johnson
15.7 Allergan plc
15.8 GlaxoSmithKline
15.9 Mylan N.V.
15.10 Pharmaxis Ltd

For more information about this report visit https://www.researchandmarkets.com/research/qdt3fv/global_cystic

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Respiratory Drugs